R&D

Research & Development

OUR APPROACH TO R&D

Our approach to R&D includes monitoring of epidemiological statistics, pharmacoeconomic analysis of the Russian and CIS healthcare systems, and examination of international studies. We scrutinize the efficacy and safety of drugs applying for inclusion in our portfolio. Our selected products undergo pre-clinical and clinical trials in their target markets, as well as trials within the marketing authorization of new products.

OUR PRODUCT PIPELINE

OUR FUTURE ROADMAP

CLINICAL TRIALS (PUBLICATIONS ARCHIVE)

Our vaccines are licensed by global industry leaders, developing a full physico-chemical characterization, a pre-clinical and clinical research program, and successfully marketed in other countries. In addition to clinical trials in the RF, we carry out our own product checks and toxicological tests. All of our products undergo post-marketing surveillance studies.
A. Rota-V-Aid
– https://www.sabin.org/sites/sabin.org/files/sajjad_desai.pdf
– https://www.nejm.org/doi/pdf/10.1056/NEJMoa1609462
– https://clinicaltrials.gov/ct2/show/NCT02145000
– https://www.clinicaltrials.gov/ct2/show/NCT02133690
– https://www.path.org/media-center/serum-institutes-vaccine-demonstrates-significant-efficacy-against-severe-rotavirus-gastroenteritis/
– https://health.economictimes.indiatimes.com/news/pharma/serums-rotavirus-vaccine-shows-significant-efficacy-gets-govt-order-for-3-8-mn-doses/60841496
B. Varicella Vaccine
– http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=12388&EncHid=&userName=CTRI/2015/07/006059
– https://trialsearch.who.int/?TrialID=CTRI/2015/07/006059
C. Vaccine against human papilloma virus
– http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=17680&EncHid=&userName=CTRI/2017/02/007785
– https://www.kemhrcvadu.org/index.php/projects/ongoing-projects/14-sample-data-articles/187-a-phase-ii-iii-partially-double-blindrandomized-active-controlled-multicentric-study-to-assess-the-immunogenicity-and-safety-of-siipl-s-qhpv-vaccine
– http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=26674&EncHid=&userName=ctri
D. Meningococcal Vaccine
– https://clinicaltrials.gov/ct2/history/NCT03295318?A=4&B=5&C=Side-by-Side#StudyPageTop
– https://clinicaltrials.gov/ct2/history/NCT03295318?A=5&B=6&C=Side-by-Side#StudyPageTop
– https://www.nejm.org/doi/10.1056/NEJMoa2013615?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed
– https://clinicaltrials.gov/ct2/show/results/NCT03295318?view=results
Pharm Aid aims to provide the Russian and CIS market with best-in-class innovative biotechnology products.

OPPORTUNITIES TO COLLABORATE

We are constantly examining new drugs, biotechnology, medical devices, diagnostics, etc. that are appearing on the global market. If you have an innovative product or solution that breaks new ground in pharmaceuticals or medicine but is not yet available in our target markets, we would be happy to discuss partnership opportunities with you.

SOME WAYS WE CAN WORK TOGETHER :

Email us at: info@pharmaid.com